MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: The MAPK pathway is activated by BCR-ABL in nilotinib-resistant chronic myeloid leukemia (CML) cells and nilotinib acts synergistically with MEK inhibitors to kill drug-resistant CML cells both in vitro and in vivo [41].